Matthew Galsky, MD, presents the case of a 55-year-old man with stage T2N0M0 muscle-invasive bladder cancer (MIBC) for review, and explains how cisplatin eligibility is defined in patients.
Cretostimogene Grenadenorepvec Shows High CR Rate in BCG-Unresponsive NMIBC
July 17th 2024Mark D. Tyson, II, MD, MPH, discussed treatment with cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ and data from the BOND-003 trial.
Read More
Immunotherapy Meets the Frontline in Bladder Cancer, Leaving Gaps in Later Lines
June 24th 2024Recent data, trials, approvals, and presentations during the 2024 American Urological Association Annual Meeting paint a positive treatment landscape for patients with metastatic and non–muscle-invasive bladder cancer.
Read More
High CR Rate in BCG-Unresponsive NMIBC With Cretostimogene Grenadenorepvec/Pembro
June 5th 2024A high complete response rate was achieved in patients with BCG–unresponsive NMIBC using the combination of cretostimogene grenadenorepvec and pembrolizumab, according to final phase 2 CORE-001 trial results.
Read More